ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
The predictive power of free (vs. total) testosterone in aggressive prostate cancer.
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 149605" data-attributes="member: 13851"><p><a href="https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e16570" target="_blank">https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e16570</a> </p><p></p><p></p><p></p><p></p><p><strong>Background:</strong> The role of testosterone in prostate growth and the development of prostate cancer is a controversial topic. <strong><span style="color: rgb(184, 49, 47)">Most current data suggest that lower testosterone leads to higher grade conversion</span>, <span style="color: rgb(44, 130, 201)">whereas higher testosterone may serve a protective role in preventing both development and recurrence.</span></strong> <span style="color: rgb(26, 188, 156)"><strong>We seek to analyze whether free testosterone (FT) values can predict aggressiveness in prostate cancers.</strong> </span></p><p></p><p><strong>Methods:</strong> We retrospectively reviewed 830 patients who presented to a single surgeon for evaluation and management of prostate cancer. Total Testosterone (TT) and FT values were obtained on each patient at initial visit. All patients underwent radical prostatectomy and samples from surgery were sent for grading and staging. Patients were stratified by FT quartile (25th [≤ 4.42 ng/dL], 50th [4.43 – 5.60 ng/dL], 75th [5.61 – 6.95 ng/dL], and 100th [≥ 6.96 ng/dL]). </p><p></p><p><strong>Results:</strong> Of 830 patients, 168 (22.2%), 330 (39.8%), 188 (22.7%), 46 (5.5%), and 98 (11.8%) had GS 3+3, 3+4, 4+3, 4+4, and ≥4+5, respectively. Mean FT values for each Gleason grade group (GGG) were significantly different (p = 0.008). Mean FT was also lower in patients with higher stage disease (p = 0.01). In contrast, TT did not differ significantly among GGG (p = 0.489) or stage (p = 0.670). Patients who had a FT level in the lowest quartile (≤ 4.42 ng/dL) had a higher proportion of GGG 5 (15.6%) than patients in the highest quartile (≥ 6.96 ng/dL) (6.2%) (p = 0.002). After adjusting for age, prostate specific antigen (PSA), and body mass index (BMI) in multivariate analysis, lower FT was a significant predictor of high-risk score 9-10 (OR: 0.912, 95% CI: 0.836-0.994, p = 0.036). These trends showed strong correlation in pathologic stage (p = 0.057), but larger numbers are needed to gauge effect size.</p><p></p><p> <strong>Conclusions: <span style="color: rgb(184, 49, 47)">Based on our data, biochemically low FT may be a risk factor for high grade and high stage cancer. </span></strong><span style="color: rgb(44, 130, 201)"><strong>These results have implications for the current recommendations for testosterone therapy, which is contraindicated in men with prostate cancer.</strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 149605, member: 13851"] [URL]https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e16570[/URL] [B]Background:[/B] The role of testosterone in prostate growth and the development of prostate cancer is a controversial topic.[COLOR=rgb(184, 49, 47)] [/COLOR][B][COLOR=rgb(184, 49, 47)]Most current data suggest that lower testosterone leads to higher grade conversion[/COLOR], [COLOR=rgb(44, 130, 201)]whereas higher testosterone may serve a protective role in preventing both development and recurrence.[/COLOR][/B] [COLOR=rgb(26, 188, 156)][B]We seek to analyze whether free testosterone (FT) values can predict aggressiveness in prostate cancers.[/B] [/COLOR] [B]Methods:[/B] We retrospectively reviewed 830 patients who presented to a single surgeon for evaluation and management of prostate cancer. Total Testosterone (TT) and FT values were obtained on each patient at initial visit. All patients underwent radical prostatectomy and samples from surgery were sent for grading and staging. Patients were stratified by FT quartile (25th [≤ 4.42 ng/dL], 50th [4.43 – 5.60 ng/dL], 75th [5.61 – 6.95 ng/dL], and 100th [≥ 6.96 ng/dL]). [B]Results:[/B] Of 830 patients, 168 (22.2%), 330 (39.8%), 188 (22.7%), 46 (5.5%), and 98 (11.8%) had GS 3+3, 3+4, 4+3, 4+4, and ≥4+5, respectively. Mean FT values for each Gleason grade group (GGG) were significantly different (p = 0.008). Mean FT was also lower in patients with higher stage disease (p = 0.01). In contrast, TT did not differ significantly among GGG (p = 0.489) or stage (p = 0.670). Patients who had a FT level in the lowest quartile (≤ 4.42 ng/dL) had a higher proportion of GGG 5 (15.6%) than patients in the highest quartile (≥ 6.96 ng/dL) (6.2%) (p = 0.002). After adjusting for age, prostate specific antigen (PSA), and body mass index (BMI) in multivariate analysis, lower FT was a significant predictor of high-risk score 9-10 (OR: 0.912, 95% CI: 0.836-0.994, p = 0.036). These trends showed strong correlation in pathologic stage (p = 0.057), but larger numbers are needed to gauge effect size. [B]Conclusions: [COLOR=rgb(184, 49, 47)]Based on our data, biochemically low FT may be a risk factor for high grade and high stage cancer. [/COLOR][/B][COLOR=rgb(44, 130, 201)][B]These results have implications for the current recommendations for testosterone therapy, which is contraindicated in men with prostate cancer.[/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Prostate Related Issues
The predictive power of free (vs. total) testosterone in aggressive prostate cancer.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top